Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although genetic factors contribute to almost half of all cases of deafness, treatment options for genetic deafness are limited. We developed a genome-editing approach to target a dominantly inherited form of genetic deafness. Here we show that cationic lipid-mediated in vivo delivery of Cas9-guide RNA complexes can ameliorate hearing loss in a mouse model of human genetic deafness. We designed and validated, both in vitro and in primary fibroblasts, genome editing agents that preferentially disrupt the dominant deafness-associated allele in the Tmc1 (transmembrane channel-like gene family 1) Beethoven (Bth) mouse model, even though the mutant Tmc1 Bth allele differs from the wild-type allele at only a single base pair. Injection of Cas9-guide RNA-lipid complexes targeting the Tmc1 Bth allele into the cochlea of neonatal Tmc1 Bth/+ mice substantially reduced progressive hearing loss. We observed higher hair cell survival rates and lower auditory brainstem response thresholds in injected ears than in uninjected ears or ears injected with control complexes that targeted an unrelated gene. Enhanced acoustic startle responses were observed among injected compared to uninjected Tmc1 Bth/+ mice. These findings suggest that protein-RNA complex delivery of target gene-disrupting agents in vivo is a potential strategy for the treatment of some types of autosomal-dominant hearing loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, lipid-mediated nanoparticle (LNP) delivery has been used to transport CRISPR-Cas components in the form of either mRNA/sgRNA or preassembled RNPs into tissues 71-74 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [74]
In the citing paper
“Additionally, lower auditory response thresholds and improved acoustic responses were observed in injected mice.[226]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [226]
In the citing paper
“The intraaural injection of Cas9 RNPs/lipofectamine 2000 complexes into the scala media of neonatal Tmc1Bth/+ mice significantly increased the survival of hair cells.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [226]
In the citing paper
“All these results demonstrated that this system substantially reduced progressive hearing loss in Beethoven mouse model (Fig. 3B) [113].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 4×
“We identified three candidate sgRNAs (Tmc1-mut1, Tmc1-mut2, and Tmc1-mut3) that place the Bth mutation at position 11, 12, or 15, respectively, of the spacer, counting the PAM as positions 21-23 (Fig.”
InfluentialImproving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“A fourth sgRNA, Tmc1-mut4, is a truncated version of Tmc1-mut3 designed to increase genome editing DNA specificity 22 .”
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Newborn Hearing Screening — A Silent Revolution
Morton, C. C., & Nance, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050700 · Cited by 1,686
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Self-citationZuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Self-citationCRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Self-citationLong, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Self-citationEfficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Self-citation
Cited by
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
Self-citationGenome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Self-citationAdvances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
Self-citationDelivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 590
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
Self-citationBase editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 469
High levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431
Treatment of a metabolic liver disease by in vivo genome base editing in adult mice
Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 429
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Precise plant genome editing using base editors and prime editors
Molla, K. A., Sretenovic, S., Bansal, K. C., & Qi, Y. (2021) · Nature Plants · doi:10.1038/s41477-021-00991-1 · Cited by 387
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Akcakaya, P., Bobbin, M. L., Guo, J. A., Malagon-Lopez, J., Clement, K., Garcia, S. P., Fellows, M. D., Porritt, M. J., Firth, M. A., Carreras, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0500-9 · Cited by 321
Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Mechanosensitive Ion Channels: Structural Features Relevant to Mechanotransduction Mechanisms
Jin, P., Jan, L. Y., & Jan, Y.-N. (2020) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050509 · Cited by 274
Cell-Type-Specific CRISPR/Cas9 Delivery by Biomimetic Metal Organic Frameworks
Alyami, M. Z., Alsaiari, S. K., Li, Y., Qutub, S. S., Aleisa, F. A., Sougrat, R., Merzaban, J. S., & Khashab, N. M. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11638 · Cited by 227
Self-citationIn vivo base editing of post-mitotic sensory cells
Yeh, W.-H., Chiang, H., Rees, H. A., Edge, A. S. B., & Liu, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-04580-3 · Cited by 225
Self-citationChitosan for gene delivery: Methods for improvement and applications
Chuan, D., Jin, T., Fan, R., Zhou, L., & Guo, G. (2019) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2019.03.007 · Cited by 212
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 209
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 205
In vivo prime editing of a metabolic liver disease in mice
Böck, D., Rothgangl, T., Villiger, L., Schmidheini, L., Matsushita, M., Mathis, N., Ioannidi, E., Rimann, N., Grisch-Chan, H. M., Kreutzer, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9238 · Cited by 198
Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss
György, B., Nist-Lund, C., Pan, B., Asai, Y., Karavitaki, K. D., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Solanes, P., Spataro, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0500-9 · Cited by 196
Self-citationAAV‐Mediated Gene Therapy Restores Hearing in Patients with DFNB9 Deafness
Qi, J., Tan, F., Zhang, L., Lu, L., Zhang, S., Zhai, Y., Lu, Y., Qian, X., Dong, W., Zhou, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202306788 · Cited by 194
Self-citationGene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
Yeh, W.-H., Shubina-Oleinik, O., Levy, J. M., Pan, B., Newby, G. A., Wornow, M., Burt, R., Chen, J. C., Holt, J. R., & Liu, D. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9101 · Cited by 185
Self-citationTargeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice
Yin, D., Ling, S., Wang, D., Dai, Y., Jiang, H., Zhou, X., Paludan, S. R., Hong, J., & Cai, Y. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00781-8 · Cited by 185
Improved TMC1 gene therapy restores hearing and balance in mice with genetic inner ear disorders
Nist-Lund, C. A., Pan, B., Patterson, A., Asai, Y., Chen, T., Zhou, W., Zhu, H., Romero, S., Resnik, J., Polley, D. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08264-w · Cited by 183
Self-citationLing, S., Yang, S., Hu, X., Yin, D., Dai, Y., Qian, X., Wang, D., Pan, X., Hong, J., Sun, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00656-y · Cited by 179
Self-citationRecent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy
Cheng, Y., Li, L., Hu, P., Yang, Y., Wei, W., Deng, X., Wang, L., Tay, F. R., & Ma, J. (2021) · Advanced Science · doi:10.1002/advs.202100540 · Cited by 177
Precision genome editing using cytosine and adenine base editors in mammalian cells
Huang, T. P., Newby, G. A., & Liu, D. R. (2021) · Nature Protocols · doi:10.1038/s41596-020-00450-9 · Cited by 175
Self-citationDevelopment of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome
Santiago-Fernández, O., Osorio, F. G., Quesada, V., Rodríguez, F., Basso, S., Maeso, D., Rolas, L., Barkaway, A., Nourshargh, S., Folgueras, A. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0338-6 · Cited by 175
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 175
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 175
Deng, S., Li, X., Liu, S., Chen, J., Li, M., Chew, S. Y., Leong, K. W., & Cheng, D. (2020) · Science Advances · doi:10.1126/sciadv.abb4005 · Cited by 169
Wang, J., & Puel, J. (2018) · Physiological Reviews · doi:10.1152/physrev.00053.2017 · Cited by 168
Current Status and Challenges of DNA Base Editing Tools
Jeong, Y. K., Song, B., & Bae, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.021 · Cited by 164
Deafness: from genetic architecture to gene therapy
Petit, C., Bonnet, C., & Safieddine, S. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00597-7 · Cited by 154
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 149
Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases
Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903618 · Cited by 147
Li, L., Yang, Z., Zhu, S., He, L., Fan, W., Tang, W., Zou, J., Shen, Z., Zhang, M., Tang, L., et al. (2019) · Advanced Materials · doi:10.1002/adma.201901187 · Cited by 147
Biopolymers based aerogels: A review on revolutionary solutions for smart therapeutics delivery
Khalil, H. P. S. A., Yahya, E. B., Jummaat, F. B., Adnan, A. S., Olaiya, N. G., Rizal, S., Abdullah, A. A., Pasquini, D., & Thomas, S. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.101014 · Cited by 146
Osteogenesis Imperfecta: Current and Prospective Therapies
Botor, M., Fus-Kujawa, A., Uroczynska, M., Stępień, K., Galicka, A., Gawron, K., & Sieroń, A. L. (2021) · Biomolecules · doi:10.3390/biom11101493 · Cited by 144
A Self-Assembled Platform Based on Branched DNA for sgRNA/Cas9/Antisense Delivery
Liu, J., Wu, T., Lu, X., Wu, X., Liu, S., Zhao, S., Xu, X., & Ding, B. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b09043 · Cited by 142
Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy
Mukalel, A. J., Riley, R. S., Zhang, R., & Mitchell, M. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.040 · Cited by 136
Inner Ear Gene Therapies Take Off: Current Promises and Future Challenges
Delmaghani, S., & El-Amraoui, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072309 · Cited by 136
Nanomaterials for Therapeutic RNA Delivery
Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 135
Osteogenesis imperfecta and therapeutics
Morello, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.010 · Cited by 135
Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 135
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Advances in gene therapy hold promise for treating hereditary hearing loss
Jiang, L., Wang, D., He, Y., & Shu, Y. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.001 · Cited by 133
Self-citationOmichi, R., Shibata, S. B., Morton, C. C., & Smith, R. J. H. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz129 · Cited by 132
Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases
Wu, S.-S., Li, Q.-C., Yin, C.-Q., Xue, W., & Song, C.-Q. (2020) · Theranostics · doi:10.7150/thno.43360 · Cited by 131
Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
Broeders, M., Herrero-Hernandez, P., Ernst, M. P. T., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2019) · iScience · doi:10.1016/j.isci.2019.100789 · Cited by 130
Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 130
Self-citationAdvancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lü, Y. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.008 · Cited by 128
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 128
Hołubowicz, R., Du, S. W., Felgner, J. H., Šmidák, R., Choi, E. H., Palczewska, G., Menezes, C. R., Dong, Z., Gao, F., Medani, O., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01296-2 · Cited by 120
Self-citationWan, T., Niu, D., Wu, C., Xu, F.-J., Church, G., & Ping, Y. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 117
Krishnamurthy, S., Wohlford-Lenane, C., Kandimalla, S., Sartre, G., Meyerholz, D. K., Théberge, V., Hallée, S., Duperré, A.-M., Del’Guidice, T., Lepetit-Stoffaes, J.-P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12922-y · Cited by 116
Naduthodi, M. I. S., Mohanraju, P., Südfeld, C., D’Adamo, S., Barbosa, M. J., & van der Oost, J. (2019) · Biotechnology for Biofuels · doi:10.1186/s13068-019-1401-3 · Cited by 112
Ling, S., Zhang, X., Dai, Y., Jiang, Z., Zhou, X., Lu, S., Qian, X., Liu, J., Selfjord, N., Şatır, T. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01851-7 · Cited by 109
Li, Y., Ye, Z., Yang, H., & Xu, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.013 · Cited by 108
Self-citationXu, Q., Zhang, Z., Zhao, L., Qin, Y., Cai, H., Geng, Z., Zhu, X., Zhang, W., Zhang, Y., Tan, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.033 · Cited by 102
Self-citationLi, C., Georgakopoulou, A., Mishra, A., Gil, S., Hawkins, R. D., Yannaki, E., & Lieber, A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003702 · Cited by 100
Santos‐Medellín, C., Blazewicz, S. J., Pett‐Ridge, J., Firestone, M. K., & Emerson, J. (2023) · Nature Ecology & Evolution · doi:10.1038/s41559-023-02207-5 · Cited by 99
Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate
Qi, J., Zhang, L., Tan, F., Zhang, Y., Zhou, Y., Zhang, Z., Wang, H., Yu, C., Jiang, L., Liu, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202306201 · Cited by 96
Self-citationXiao, Q., Xu, Z., Xue, Y., Xu, C., Han, L., Liu, Y., Wang, F., Zhang, R., Han, S., Wang, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn0449 · Cited by 95
Self-citationYoshimura, H., Shibata, S. B., Ranum, P. T., Moteki, H., & Smith, R. J. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.014 · Cited by 95
Liu, Z., Zhou, W. Y., Cheng, Q., & Kong, T. (2020) · Advanced Materials · doi:10.1002/adma.202002932 · Cited by 94
Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences
Tavakoli, K., Pour‐Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021) · BioTech · doi:10.3390/biotech10030014 · Cited by 94
Li, Y., Bolinger, J., Yu, Y., Glass, Z., Shi, N., Yang, L., Wang, M., & Xu, Q. (2019) · Biomaterials Science · doi:10.1039/c8bm00637g · Cited by 94
Self-citationInner Ear Drug Delivery for Sensorineural Hearing Loss: Current Challenges and Opportunities
Liu, S. S., & Yang, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.867453 · Cited by 90
New molecular therapies for the treatment of hearing loss
Ma, Y., Wise, A. K., Shepherd, R. K., & Richardson, R. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.003 · Cited by 89
Cardiovascular Disease in Duchenne Muscular Dystrophy
Schultz, T., Raucci, F. J., & Salloum, F. N. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.11.004 · Cited by 87
Gene Therapy for Human Sensorineural Hearing Loss
Ren, Y., Landegger, L. D., & Stanković, K. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00323 · Cited by 86
Disease mechanisms and gene therapy for Usher syndrome
Géléoc, G. S. G., & El-Amraoui, A. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107932 · Cited by 86
Targeting fidelity of adenine and cytosine base editors in mouse embryos
Lee, H. K., Willi, M., Miller, S. M., Kim, S., Liu, C., Liu, D. R., & Hennighausen, L. (2018) · Nature Communications · doi:10.1038/s41467-018-07322-7 · Cited by 85
Self-citationRecent advances in CRISPR/Cas9-mediated knock-ins in mammalian cells
Banan, M. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.11.010 · Cited by 85
The virtuous cycle of human genetics and mouse models in drug discovery
Nadeau, J. H., & Auwerx, J. H. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0009-9 · Cited by 84
Single and Dual Vector Gene Therapy with AAV9-PHP.B Rescues Hearing in Tmc1 Mutant Mice
Wu, J. H., Solanes, P., Nist-Lund, C. A., Spataro, S., Shubina-Oleinik, O., Marcovich, I., Goldberg, H., Schneider, B. L., & Holt, J. R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.016 · Cited by 84
Self-citationAkram, F., Sahreen, S., Aamir, F., Haq, I. U., Malik, K. A., Imtiaz, M., Naseem, W., Nasir, N., & Waheed, H. M. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00501-4 · Cited by 83
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
Samarajeewa, A., Jacques, B. E., & Dabdoub, A. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.017 · Cited by 82
Gene editing in a Myo6 semi-dominant mouse model rescues auditory function
Xue, Y., Hu, X., Wang, D., Li, D., Li, Y., Wang, F., Huang, M., Gu, X. G., Xu, Z., Zhou, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.015 · Cited by 80
Self-citationQiao, J., Sun, W., Lin, S., Jin, R., Ma, L., & Liu, Y. (2019) · Chemical Communications · doi:10.1039/c9cc00010k · Cited by 79
Adhesive and Injectable Hydrogel Microspheres for Inner Ear Treatment
Chen, K., Wang, F., Ding, R., Cai, Z., Zou, T., Zhang, A., Guo, D., Ye, B., Cui, W., & Xiang, M. (2022) · Small · doi:10.1002/smll.202106591 · Cited by 79
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
Bloomer, H., Khirallah, J., Li, Y., & Xu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114087 · Cited by 78
Self-citationRoccio, M., & Edge, A. S. B. (2019) · Development · doi:10.1242/dev.177188 · Cited by 78
Genetic insights, disease mechanisms, and biological therapeutics for Waardenburg syndrome
Huang, S., Song, J. H., He, C., Cai, X., Yuan, K., Mei, L., & Feng, Y. (2021) · Gene Therapy · doi:10.1038/s41434-021-00240-2 · Cited by 78
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
Self-citationAllemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症:英文版 · doi:10.1002/cac2.12366 · Cited by 77
Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 76
Application of Non-Viral Vectors in Drug Delivery and Gene Therapy
Ren, S., Wang, M., Wang, C., Wang, Y., Sun, C., Zeng, Z., Cui, H., & Zhao, X. (2021) · Polymers · doi:10.3390/polym13193307 · Cited by 76
Metadata
- Authors
- Gao, X., Tao, Y., Lamas, V., Huang, M., Yeh, W.-H., Pan, B., Hu, Y.-J., Hu, J. H., Thompson, D. B., Shu, Y., Li, Y., Wang, H., Yang, S., Xu, Q., Polley, D. B., Liberman, M. C., Kong, W.-J., Holt, J. R., Chen, Z.-Y., & Liu, D. R.
- Affiliations
- Broad Institute (US)
- Massachusetts Eye and Ear Infirmary (US)
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Tufts University (US)
- Corresponding author
- Chen, Zheng-Yi
- Liu, David R.
- ORCID
- Venue
- Nature
- Published
- 2017-12-20
- Volume
- 553
- Issue
- 7687
- Pages
- 217-221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5784267
- OpenAlex
- W2778806019
- Cited by
- 536
- References
- 28
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 58 · 2023: 62 · 2022: 64 · 2021: 60 · 2020: 101 · 2019: 67 · 2018: 54 · 2017: 1
- FWCI
- 37.88
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (2r01dc013521-11a1)
- National Institute on Deafness and Other Communication Disorders (R01-DC013521, R01DC009836, P30DC005209, R01DC006908, F32DC000138, R01DC000188)
- National Institute of General Medical Sciences (R35GM118062)
- National Institute of Biomedical Imaging and Bioengineering (R01EB022376)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090255)
- Topics
- Life Sciences › Neuroscience › Sensory Systems › Hearing, Cochlea, Tinnitus, Genetics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- autosomal dominant hearing loss, CRISPR/Cas9 genome editing, in vivo gene delivery, dominant negative mutation, auditory brainstem response, acoustic startle response
- MeSH terms
- Gene Editing, Acoustic Stimulation, Alleles, Animals, Animals, Newborn, Auditory Threshold, Base Sequence, Cell Survival, Cochlea, Disease Models, Animal, Female, Fibroblasts, Genes, Dominant, Hair Cells, Auditory, Humans, Liposomes, Male, Membrane Proteins, Reflex, Startle, Genetic Therapy, Evoked Potentials, Auditory, Brain Stem, Hearing Loss, Mice, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.